Evidence map›Paper›PMID 40822334›Full record

ArticleiScience2025

Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00.

Andrea Joaquin Garcia, Takashi Semba, Mattia Rediti, Daniel J McGrail, Xuemei Xie, Xiaoping Wang, Dileep R Rampa, David Venet, Laurence Buisseret, Samira Majjaj and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Andrea Joaquin GarciaBreast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Takashi SembaSection of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mattia ReditiBreast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Daniel J McGrailLerner Research Institute, Cleveland, OH, USA.
Xuemei XieCancer Biology Program, University of Hawai'i Cancer Center, Honolulu, HI, USA.
Xiaoping WangCancer Biology Program, University of Hawai'i Cancer Center, Honolulu, HI, USA.
Dileep R RampaCancer Biology Program, University of Hawai'i Cancer Center, Honolulu, HI, USA.
David VenetBreast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Laurence BuisseretBreast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Samira MajjajBreast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Roswitha KammlerTranslational Research Coordination International Breast Cancer Study Group, Division of ETOP IBCSG Partners Foundation, Bern, Switzerland.
Marco ColleoniInternational Breast Cancer Study Group, Division of Medical Senology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Sherene LoiInternational Breast Cancer Study Group, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
Giuseppe VialeIEO European Institute of Oncology IRCCS, Milan, Italy.
Meredith M ReganInternational Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Françoise RothéBreast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Christos SotiriouBreast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Naoto T UenoCancer Biology Program, University of Hawai'i Cancer Center, Honolulu, HI, USA.

Funding

Developing a novel combination immunotherapy for triple-negative breast cancerR01CA278056 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Naoto T. Ueno · 2023 to 2026
$2.6M
NCI NIH HHS R01 CA278056
6 · The paper itself

Abstract

Phosphorylation of the JNK (pJNK) protein promotes an immunosuppressive tumor microenvironment (TME), enhancing aggressiveness in inflammatory triple-negative breast cancer (TNBC). This study evaluated the role of JNK signaling using a gene signature. RNA sequencing was performed on 347 TNBC tumors from the phase 3 International Breast Cancer Study Group (IBCSG) 22-00 trial, which evaluated adjuvant low-dose cyclophosphamide and methotrexate (CM). Immune-related tumors were identified by TNBC subtype or tumor-infiltrating lymphocytes (TILs). Associations between JNK and outcomes were analyzed using Cox models. Low pJNK levels were associated with better disease-free survival (DFS) in immune-related tumors. These tumors also had lower Treg levels and higher CD8

Indexed as

CancerImmunologyTranscriptomics

Identifiers

PMID40822334
PMCPMC12355117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.